Halozyme Therapeutics, Inc. (HALO)

In the past six months, Halozyme's stock has trended down by 15.28%. Key events include the Q4 and Full Year 2025 Financial Results, which reported record total revenue but a net loss in Q4 due to IPR&D expenses. Halozyme expanded its drug delivery technology portfolio through acquisitions in late 2025. Johnson & Johnson received FDA approval for TECVAYLI in combination with DARZALEX FASPRO, utilizing Halozyme's technology. A German court granted Halozyme's request for a preliminary injunction, ordering Merck Sharp & Dohme Corp. to refrain from distributing and offering Keytruda® SC in Germany.

Demand for Halozyme Therapeutics' products and services exhibits some seasonality, with product sales and collaboration revenue generally expected to be more weighted towards the fourth quarter.

Halozyme Therapeutics, Inc. is an American biopharmaceutical technology platform company headquartered in San Diego, California, operating within the Health Technology, Biotechnology, and Pharmaceuticals sectors. Its core business revolves around its proprietary ENHANZE® drug delivery technology, which utilizes the recombinant human hyaluronidase enzyme, rHuPH20, to facilitate the subcutaneous administration of injected drugs and fluids. Halozyme develops, manufactures, and commercializes drug-device combination products, including Hylenex® recombinant and XYOSTED®. The company also focuses on developing oncology therapies and licenses its ENHANZE® technology to other biopharmaceutical companies.

Halozyme Therapeutics, Inc. is headquartered in San Diego, California, United States, and operates on a global scale, with collaborations and market presence spanning North America and other regions. Its stock is listed on multiple exchanges, including NasdaqGS (United States), Deutsche Boerse AG (Germany), London Stock Exchange (United Kingdom), Mexico Stock Exchange (Mexico), and Borsa Italiana (Italy).

Halozyme Therapeutics has generally maintained a strong brand reputation over the past year, driven by its robust financial performance and innovative technology. Key events that have positively impacted its reputation include record revenue in 2025, strategic acquisitions, FDA approval of partnered products, and intellectual property defense. While the company reported a non-GAAP loss in Q4 2025, the overall financial trajectory and strategic advancements suggest a positive brand perception.

Halozyme Therapeutics, Inc. has a strong presence of institutional investors, with 755 institutional owners and shareholders holding a total of 126,099,413 shares, accounting for 83.99% of the company. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, and State Street Corp. Individual ownership accounts for 1.13% of the company.